New hope for KRAS lung cancer: targeted drug combo enters final trial phase
Disease control
Recruiting now
This study tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific genetic form of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had prior treatmen…
Phase: PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC